Showing results (61-70 of 225) with videos related to
Sort By:
Pageof 23
Expert Review of Anticancer Therapy|December 21, 2017
The development of PARP as a successful target for cancer therapyRoberto Ferrara, Francesca Simionato, Chiara Ciccarese, et al.Cancer Treatment Reviews|February 24, 2017
Prostate cancer heterogeneity: Discovering novel molecular targets for therapyChiara Ciccarese, Francesco Massari, Roberto Iacovelli, et al.Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada|March 29, 2014
Clinical outcomes in patients with metastatic renal cell carcinoma receiving everolimus or temsirolimus after sunitinibRoberto Iacovelli, Giacomo Cartenì, Michele Milella, et al.Current Cancer Drug Targets|January 8, 2025
The Clinical Role of Hypoxia Inducible Factor (HIF) Inhibition in Renal Cancer: A Focus on BelzutifanDaniela Arduini, Chiara Ciccarese, Alessandro Strusi, et al.Cancer Treatment Reviews|September 28, 2013
Targeted therapies and complete responses in first line treatment of metastatic renal cell carcinoma. A meta-analysis of published trialsRoberto Iacovelli, Daniele Alesini, Antonella Palazzo, et al.Therapeutic Advances in Urology|February 14, 2018
Circulating tumor cells in genitourinary tumorsFrancesco Massari, Vincenzo Di Nunno, Francesca Comito, et al.Minerva Urology and Nephrology|February 22, 2020
Adverse events related to radium-223 treatment: "real-life" data from the Eudra-Vigilance databaseGiorgia Tema, Riccardo Lombardo, Olivia Voglino, et al.Oncology|November 8, 2014
Time from nephrectomy as a prognostic factor in metastatic renal cell carcinoma patients receiving targeted therapies: overall results from a large cohort of patientsGiuseppe Procopio, Isabella Testa, Elena Verzoni, et al.European Urology|September 3, 2013
Tumor growth rate provides useful information to evaluate sorafenib and everolimus treatment in metastatic renal cell carcinoma patients: an integrated analysis of the TARGET and RECORD phase 3 trial dataCharles Ferté, Serge Koscielny, Laurence Albiges, et al.Journal of Immunotherapy (Hagerstown, Md. : 1997)|February 22, 2020
The Anticancer Efficacy of Immune Checkpoint Inhibitors According to Patients' Age: A Systematic Review and Meta-AnalysisChiara Ciccarese, Roberto Iacovelli, Emilio Bria, et al.Pageof 23